US 12,251,402 B2
Mesenchymal stem cells with enhanced immunosuppressive capability
Basil M. Hantash, East Palo Alto, CA (US)
Assigned to Escape Therapeutics, Inc., Turlock, CA (US)
Filed by Escape Therapeutics, Inc., San Jose, CA (US)
Filed on Jan. 23, 2020, as Appl. No. 16/750,554.
Application 16/750,554 is a division of application No. 15/250,441, filed on Aug. 29, 2016, granted, now 10,576,105.
Claims priority of provisional application 62/213,748, filed on Sep. 3, 2015.
Prior Publication US 2020/0155610 A1, May 21, 2020
Int. Cl. A61K 35/28 (2015.01); A61K 9/00 (2006.01); A61K 35/12 (2015.01); C12N 5/0775 (2010.01)
CPC A61K 35/28 (2013.01) [A61K 9/0019 (2013.01); C12N 5/0663 (2013.01); C12N 5/0667 (2013.01); A61K 2035/124 (2013.01); C12N 2501/70 (2013.01)] 13 Claims
 
1. A method of transplanting a composition comprising a population of mesenchymal stem cells (MSCs), the method comprising injecting the composition into a human recipient, wherein the population of MSCs comprises MSCs that express HLA-G (HLA-G+ MSCs), wherein the population of MSCs was contacted with a DNA methylation inhibitor prior to the injection, and wherein the HLA-G+ MSCs have (a) a methylation level at least 5% lower than MSCs that have not been contacted with the DNA methylation inhibitor and (b) HLA-G expression at least 10% higher than MSCs that have not been contacted with the DNA methylation inhibitor.